Showing 1 - 2 results of 2 for search 'Karen A. Autio', query time: 0.01s Refine Results
  1. 1
    Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer

    Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer by Karen A. Autio, Deaglan J. McHugh, Dana E. Rathkopf, Han Xiao, Swathi Merugu, Phillip Wong, Mehrin Jan, Tanya B. Dorff, Elisabeth I. Heath, Howard I. Scher

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

    CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study by Omid Hamid, Fiona Thistlethwaite, Johanna Bendell, Ruth Plummer, Patrick A Ott, Rachel E Sanborn, Karen A Autio, Valentina Boni, Elisabeth GE de Vries, Javier Garcia-Corbacho, Daniel C Cho, Mark Stroh, Lawrence Lu

    Published 2021-07-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: